Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (2988)	11/25/1997 2:00:00 PM
From: Richard Monge	Read Replies (2) \| Respond to of 6136

Steve, John, anyone What is Rhinovirus? What market will it serve? Also What is Thymitaq? Sorry for the question, New investor in AGPH

To: Steve Fancy who wrote (2988)	11/25/1997 4:57:00 PM
From: Zirdu	Read Replies (2) \| Respond to of 6136

Steve, I don't understand your comments about the E. Wang call. You say: " Maintaining 12-month price target of 75 based on fiscal '98 $4.00 and change and industry multiple in the mid 40's. - Expect strong earnings report in early January...her estimate .12, if not better...expect stock to rebound strongly." Is she really saying that FY '98 earnings will be $4.00 and change? So far we have 1Q98 earnings of .11, and if she expects only .12 for 2Q, that will leave a lot of earnings for Q3 and Q4 to make over $4.00. Also, earnings of $4.00 and a PE of 45 would give a stock price of $180, not $75. Something dosn't add up here. Could you clarify exactly what she said in this regard? Thanks. RR